As CYLD is expressed in multiple cell types beyond tumor cells, including T and B cells, with potentially pleiotropic functions across cell types, it would be important to improve CYLD-targeting specificity (47) with tumor-targeting strategies such as antibody drug conjugates to reduce on-target, off-tumor toxicity to achieve both therapeutic efficacy and safety. This evidence concerns the gene CYLD and neoplasm.